Breaking: Positive topline data from our Phase 2b study of BPL-003 in treatment-resistant depression. A key step toward Phase 3 and our mission to deliver faster, longer-lasting psychedelic treatments to those who need them most.

Our CEO & Co-Founder, Cosmo Feilding Mellen, joined @Labiotech_eu’s Beyond Biotech podcast to discuss how next-gen psychedelics could help patients with treatment-resistant depression. Listen here #MentalHealth #Psychedelics #Biotech.

RT @C_Angermayer: Today, $ATAI announced outstanding Phase 2b data for BPL-003 (5-MeO-DMT). In parallel, core shareholders – including mys….

We’re proud to join @MentalHealthAm's Regional Policy Council - a national network shaping mental health policy through lived experience, collaboration and innovation. Together, we aim to ensure emerging treatments lead to real-world impact.

Prof. John Marsden (King’s College London) and Dr. Anya Ermakova (Beckley Psytech) will be sharing novel clinical and micro-phenomenological data from our Phase IIa study of BPL-003 for Alcohol Use Disorder at the 2025 CPDD Annual Meeting. 🔗 Learn more:

NEWS: Beckley Psytech and @atai_life ($ATAI) to combine to form a global leader in psychedelic mental health therapies. Together, we’re accelerating innovation for those in need. Learn more:

Today we announced positive topline results from our Phase IIa study of BPL-003 in combination with SSRIs for treatment resistant depression. Read more on our website:

We will be presenting data from our Phase IIa study of BPL-003 for TRD at #SOBP2025 in Toronto tomorrow at 5pm EDT. Looking forward to connecting with the scientific community.

It's Brain Awareness Week - the perfect time to highlight the first-of-its-kind brain imaging study going on at @imperialcollege with BPL-003. Check out our Q&A with the experts behind the study (@neurodelia, @tommaso_barba) below.

We have completed enrolment in the core stage of our Phase IIb study of BPL-003 for Treatment Resistant Depression. Grateful to our trial participants & partners who made this study happen!

Today is International Day of Women and Girls in Science! 🌍🔬 At Beckley Psytech, we’re celebrating the brilliant women in our team who are shaping the future of science. Hear about some of their experiences below. #IDWGS #WomenInSTEM

Topline data from our Phase IIa study of BPL-003 for Alcohol Use Disorder show that a single dose was well-tolerated and delivered a meaningful and sustained reduction in alcohol use and Heavy Drinking Days over a 3-month evaluation period.

Initial findings from our Phase IIa study of ELE-101 for depression shows that a single 10-minute infusion is well-tolerated, induces rapid and lasting antidepressant effects, and allows patients to be ready for discharge in ~2 hours. Read more here:

🎙️ In this fascinating episode of @healthtechpod with @JamesSomauroo, our CEO, Cosmo Feilding Mellen, shares his insights on psychedelics, consciousness, and mental health innovation. 🎧 Listen here:

ICYMI: Our CEO, Cosmo Feilding Mellen, caught up with @TIME to discuss how our novel short-acting, psychedelic-based therapies could revolutionise the treatment of mental health conditions. Learn more here:

In this fascinating interview, Cosmo Feilding Mellen shares his journey from growing up at the heart of the psychedelic revolution to leading the charge in plant-based medicine. YT: Spotify: Apple:

How do you progress a psychedelic-based treatment through development and onto patients in need? . Find out in the 'Power to the Patients' with our CEO, Cosmo Feilding Mellen, and Brandon Li. Full episode here:

Today is #WorldMentalHealthDay! We spoke with our CSMO, Dr. Rob Conley, about the latest in mental health treatments for depression & substance use disorders - and his hopes for the future. Read the full Q+A here:

Good luck to Anya Ermakova, Research Scientist at Beckley Psytech, who will be sharing her microphenomenology research from our Phase I study of BPL-003 at Mind and Life Europe’s event ‘Becoming Aware and Micro-Phenomenology: Process, Practice, Outcomes’ this weekend.

How might next-generation psychedelics revolutionise the treatment of mental health conditions? . Find out what our CEO, Cosmo Feilding Mellen, thinks in @TIME today:.